Centrus Energy, supplier of nuclear fuel components and services for the nuclear power industry that is also conducting a High-Assay, Low-Enriched Uranium (HALEU) enrichment demonstration program for the U.S. Department of Energy, announced that Daniel B. Poneman, President and Chief Executive Officer, and Philip Strawbridge, Chief Financial Officer, are scheduled to present at the Lake Street 5th Annual Best Ideas Growth (BIG5) Conference.
Centrus Energy Corp. will broadcast its quarterly conference call with shareholders and the financial community over the Internet on Thursday, August 12, 2021, at 8:30 a.m. ET. The Company will release its second quarter earnings report for 2021, which ended June 30, 2021, after the close of markets on Wednesday, August 11.
BETHESDA, Md. – Centrus Energy Corp. announced the results of its 2021 annual meeting of stockholders held on June 16, 2021. As of April 19, 2021, the meeting’s record date, there were 12,918,602 shares of the Company’s Class A common stock outstanding, each entitled to one vote, and approximately 79.8 percent of those shares were represented at the annual meeting.
Centrus Energy Corp. announced that the U.S. Nuclear Regulatory Commission (NRC) approved the Company’s license amendment request to produce High-Assay, Low-Enriched Uranium (HALEU) at the Piketon, Ohio, enrichment facility. The Piketon plant is now the only U.S. facility licensed to enrich uranium up to 20 percent Uranium-235 (U-235) and expects to begin demonstrating HALEU production early next year.
BETHESDA, Md. - Centrus Energy Corp. (NYSE American: LEU) is providing an update on construction of the nation’s first production facility for High-Assay, Low-Enriched Uranium (HALEU) in Piketon, Ohio.
“Despite the impact of the pandemic and the extraordinary steps we have taken to protect our workforce – including limiting the number of people who can be on the construction site at any one time – we have kept construction on track and expect to begin producing HALEU by next year,” said Centrus President and CEO Daniel B. Poneman. “We believe this first-of-a-kind facility can play a critical role in meeting both government and commercial requirements for HALEU, powering America’s nuclear leadership as the world turns to a new generation of advanced reactors and advanced nuclear fuels.”
“Despite the unprecedented health crisis posed by COVID-19, with a large portion of our staff shifting to telework, Centrus has had a great year that saw us return to profitability, improve our balance sheet, and deliver value to stockholders with a higher share price,” said Daniel Poneman, Centrus President and Chief Executive Officer. “Our technical solutions team continues to make strong progress on the High-Assay, Low-Enriched Uranium (HALEU) program and we expect to begin demonstrating production of HALEU by early next year. Our sales team also secured over $100 million in new commitments from November through the end of January.”